PHARMACOKINETICS AND METABOLISM OF QUINIDINE IN EXTENSIVE AND POOR METABOLIZERS OF SPARTEINE

被引:46
作者
MIKUS, G
HA, HR
VOZEH, S
ZEKORN, C
FOLLATH, F
EICHELBAUM, M
机构
[1] KANTONSSPITAL,DEPT INNERE MED,DIV CLIN PHARMACOL,CH-4004 BASEL,SWITZERLAND
[2] UNIV BONN,MED KLIN,D-5300 BONN,FED REP GER
关键词
D O I
10.1007/BF00870989
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:69 / 72
页数:4
相关论文
共 15 条
[1]   GENETIC-POLYMORPHISM IN DRUG OXIDATION - INVITRO STUDIES OF HUMAN DEBRISOQUINE 4-HYDROXYLASE AND BUFURALOL 1'-HYDROXYLASE ACTIVITIES [J].
BOOBIS, AR ;
MURRAY, S ;
HAMPDEN, CE ;
DAVIES, DS .
BIOCHEMICAL PHARMACOLOGY, 1985, 34 (01) :65-71
[2]   EFFECT OF OXIDATIVE POLYMORPHISM (DEBRISOQUINE SPARTEINE TYPE) ON HEPATIC 1ST-PASS METABOLISM OF BUFURALOL [J].
DAYER, P ;
BALANT, L ;
KUPFER, A ;
STRIBERNI, R ;
LEEMANN, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (03) :317-320
[3]   INFLUENCE OF THE DEFECTIVE METABOLISM OF SPARTEINE ON ITS PHARMACOKINETICS [J].
EICHELBAUM, M ;
SPANNBRUCKER, N ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :189-194
[4]   POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE - RELATED PHARMACOGENETIC ENTITIES [J].
EICHELBAUM, M ;
BERTILSSON, L ;
SAWE, J ;
ZEKORN, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (02) :184-186
[5]  
EICHELBAUM M, 1984, FED PROC, V43, P2298
[6]  
EICHELBAUM M, 1982, CLIN PHARMACOKINET, V7, P1, DOI 10.2165/00003088-198207010-00001
[7]  
IDLE JR, 1984, 2ND P WORLD C CLIN P, P148
[8]   A HUMAN CYTOCHROME-P-450 CHARACTERIZED BY INHIBITION STUDIES AS THE SPARTEINE DEBRISOQUINE MONOOXYGENASE [J].
INABA, T ;
NAKANO, M ;
OTTON, SV ;
MAHON, WA ;
KALOW, W .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1984, 62 (07) :860-862
[9]   DEFECTIVE METABOLISM OF METOPROLOL IN POOR HYDROXYLATORS OF DEBRISOQUINE [J].
LENNARD, MS ;
SILAS, JH ;
FREESTONE, S ;
TREVETHICK, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 14 (02) :301-303
[10]  
LEROYER R, 1982, J CHROAMTOGR BIOCH A, V228, P336